|
| 31879235 | Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. | Alzheimers Dement | 2020 |
| 29799984 | Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. | JAMA Neurol | 2018 |
| 28787712 | Effectiveness of Florbetapir PET Imaging in Changing Patient Management. | Dement Geriatr Cogn Disord | 2017 |
| 28124589 | Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease. | Curr Alzheimer Res | 2017 |
| 29182706 | Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. | J Prev Alzheimers Dis | 2017 |
| 28795133 | Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. | Alzheimers Dement (Amst) | 2017 |
| 26967206 | Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. | J Alzheimers Dis | 2016 |
| 29210443 | Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. | J Prev Alzheimers Dis | 2016 |
| 24526759 | Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease. | Am J Alzheimers Dis Other Demen | 2015 |
| 27239520 | A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings. | Alzheimers Dement (Amst) | 2015 |
| 25973909 | Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. | Alzheimer Dis Assoc Disord | 2015 |
| 25675992 | Evaluating Response to High-Dose 13.3Â mg/24Â h Rivastigmine Patch in Patients with Severe Alzheimer's Disease. | CNS Neurosci Ther | 2015 |
| 25622185 | Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. | JAMA Neurol | 2015 |
| 25437301 | A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease. | Alzheimer Dis Assoc Disord | 2015 |
| 24335535 | Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. | J Neuropathol Exp Neurol | 2014 |
| 25667813 | Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia. | Prim Care Companion CNS Disord | 2014 |
| 24614494 | Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. | Mol Psychiatry | 2014 |
| 24549933 | Efficacy of higher-dose 13.3â¿¿mg/24 h (15â¿¿cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis. | Int J Geriatr Psychiatry | 2014 |
| 22633529 | Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. | Neurobiol Aging | 2013 |
| 24280255 | The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. | Alzheimers Res Ther | 2013 |
| 23924050 | A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. | CNS Neurosci Ther | 2013 |
| 23750151 | Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: an exploratory study. | Front Neurol | 2013 |
| 23203162 | Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. | Alzheimer Dis Assoc Disord | 2013 |
| 23375563 | Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. | Alzheimers Dement | 2013 |
| 22878163 | Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. | Neurobiol Aging | 2013 |
| 22343285 | Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. | Proc Natl Acad Sci U S A | 2012 |
| 22786606 | Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. | Neurology | 2012 |
| 22749065 | Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. | Lancet Neurol | 2012 |
| 22570400 | Practical guidelines for the recognition and diagnosis of dementia. | J Am Board Fam Med | 2012 |
| 22570399 | Guidelines for the management of cognitive and behavioral problems in dementia. | J Am Board Fam Med | 2012 |
| 22607530 | Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine. | Headache | 2012 |
| 22331215 | Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. | J Nucl Med | 2012 |
| 21646051 | Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. | Alzheimers Dement | 2011 |
| 21977379 | Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis. | Prim Care Companion CNS Disord | 2011 |
| 20070789 | Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. | CNS Neurosci Ther | 2010 |
| 21274364 | Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. | Prim Care Companion J Clin Psychiatry | 2010 |
| 20089009 | Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. | Int J Clin Pract | 2010 |
| 20102418 | Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. | Int J Clin Pract | 2010 |
| 19293130 | Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. | Am J Alzheimers Dis Other Demen | 2009 |
| 19484917 | Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. | Alzheimer Dis Assoc Disord | 2009 |
| 18036286 | A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. | Curr Med Res Opin | 2008 |
| 18787673 | Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. | Prim Care Companion J Clin Psychiatry | 2008 |
| 17380489 | A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. | Int J Geriatr Psychiatry | 2007 |
| 16772745 | A cost effective method of identifying and recruiting persons over 80 free of dementia or mild cognitive impairment. | Alzheimer Dis Assoc Disord | 2006 |
| 15841194 | Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study. | Prim Care Companion J Clin Psychiatry | 2005 |
| 16327345 | The validation of a caregiver assessment of dementia: the Dementia Severity Scale. | Alzheimer Dis Assoc Disord | 2005 |
| 12682308 | DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. | Neurology | 2003 |
| 11318886 | Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. | Headache | 2001 |
| 9236571 | Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. | Arch Neurol | 1997 |
| 8161382 | Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. | Am J Emerg Med | 1994 |